The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials
Background: This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Tr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1157251/full |
| _version_ | 1827941718549331968 |
|---|---|
| author | Jingyue Qiu Dandan Sheng Fei Lin Fei Lin Peng Jiang Ning Shi |
| author_facet | Jingyue Qiu Dandan Sheng Fei Lin Fei Lin Peng Jiang Ning Shi |
| author_sort | Jingyue Qiu |
| collection | DOAJ |
| description | Background: This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Trials Registry Platform were searched up to 25 October 2022. Only randomized controlled trials (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus chemotherapy for treating malignant cancers in adult patients were included. The primary outcome included the incidence of SN, FN, the DSN, and administration of ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes included the risk of adverse events (AEs) and severe adverse events (SAEs).Results: In total, four randomized controlled trials (RCTs) involving 345 patients with SCLC or breast cancer were included in this meta-analysis. Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was also statistically lower in the experimental group than in the control group. Meanwhile, the ORR, overall survival, and progress-free survival of the two groups were identical, and no negative impact of Trilaciclib on the clinical outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and vomiting were identical regardless of Trilaciclib usage.Conclusion: Trilaciclib demonstrated its efficacy in reducing the occurrence of chemotherapy-induced myelosuppression and utilization of supportive care interventions without undermining the clinical benefits of chemotherapy regimens during treatment with an acceptable safety profile. |
| first_indexed | 2024-03-13T09:46:53Z |
| format | Article |
| id | doaj.art-c95bbb41321d41c5bb25065594e32bbc |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T09:46:53Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c95bbb41321d41c5bb25065594e32bbc2023-05-25T04:14:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-05-011410.3389/fphar.2023.11572511157251The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trialsJingyue Qiu0Dandan Sheng1Fei Lin2Fei Lin3Peng Jiang4Ning Shi5Pharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, ChinaPharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaClinical Medical College, Chengdu Medical College, Chengdu, ChinaMedical Team, PLA Strategic Support Force Integrated Training Team, Beijing, ChinaPharmaceutical Department, PLA Strategic Support Force Medical Center, Beijing, ChinaBackground: This study aims to assess the clinical efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane Library, Clinical Trials, EU Clinical Trials Register, and International Clinical Trials Registry Platform were searched up to 25 October 2022. Only randomized controlled trials (RCTs) comparing the clinical outcomes of Trilaciclib and Trilaciclib plus chemotherapy for treating malignant cancers in adult patients were included. The primary outcome included the incidence of SN, FN, the DSN, and administration of ESAs, G-CSFs, and RBC or platelet transfusions, while the secondary outcomes included the risk of adverse events (AEs) and severe adverse events (SAEs).Results: In total, four randomized controlled trials (RCTs) involving 345 patients with SCLC or breast cancer were included in this meta-analysis. Results showed that administration of Trilaciclib significantly reduced the occurrence of SN (19.3% vs. 42.2%, OR = 0.31), FN (3.22% vs. 6.72%, OR = 0.47), anemia (20.5% vs. 38.2%, OR = 0.38) and shortened the DSN during treatment. The proportion of patients receiving therapeutic use of ESAs (4.03% vs. 11.8%, OR = 0.31), G-CSF (37.0% vs. 53.5%, OR = 0.52), RBC transfusions (19.8% vs. 29.9%, OR = 0.56) was also statistically lower in the experimental group than in the control group. Meanwhile, the ORR, overall survival, and progress-free survival of the two groups were identical, and no negative impact of Trilaciclib on the clinical outcomes of chemotherapy treatments was found. Other chemotherapy-induced adverse events (AEs) and severe adverse events (SAEs) like diarrhea, fatigue, nausea, and vomiting were identical regardless of Trilaciclib usage.Conclusion: Trilaciclib demonstrated its efficacy in reducing the occurrence of chemotherapy-induced myelosuppression and utilization of supportive care interventions without undermining the clinical benefits of chemotherapy regimens during treatment with an acceptable safety profile.https://www.frontiersin.org/articles/10.3389/fphar.2023.1157251/fullCDK4/6 inhibitortrilaciclibchemotherapymyelosuppressionmeta-analysis |
| spellingShingle | Jingyue Qiu Dandan Sheng Fei Lin Fei Lin Peng Jiang Ning Shi The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials Frontiers in Pharmacology CDK4/6 inhibitor trilaciclib chemotherapy myelosuppression meta-analysis |
| title | The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials |
| title_full | The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials |
| title_short | The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of trilaciclib in preventing chemotherapy induced myelosuppression a systematic review and meta analysis of randomized controlled trials |
| topic | CDK4/6 inhibitor trilaciclib chemotherapy myelosuppression meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1157251/full |
| work_keys_str_mv | AT jingyueqiu theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT dandansheng theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT pengjiang theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ningshi theefficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jingyueqiu efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT dandansheng efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT pengjiang efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ningshi efficacyandsafetyoftrilaciclibinpreventingchemotherapyinducedmyelosuppressionasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |